AuraVax Therapeutics announced that the US Department of Health and Human Services' Biomedical Advanced Research and Development Authority (BARDA) has awarded the company a preclinical research contract to support evaluation of AuraVax's NanoSTING-002 mucosal adjuvant with Codagenix's intranasal live attenuated influenza virus (LAIV). In early 2021, AuraVax announced … [Read more...] about AuraVax gets BARDA contract to test its NanoSTING-002 mucosal adjuvant with Codagenix’s intranasal flu vaccine
News
Vaxinano raises €6 million for development of intranasal vaccines
French vaccine developer Vaxinano announced that it has raised €6 million to support clinical development of several intranasal vaccine candidates based on the Stellar-NP nanoparticle platform. The company's pipeline includes nasal vaccines against zoonotic diseases and parasites such as leishmaniasis and toxoplasmosis, with the majority of Vaxinano's vaccines … [Read more...] about Vaxinano raises €6 million for development of intranasal vaccines
Agomab raises $89 million for development of candidates including AGMB-447 inhaled ALK5 inhibitor for IPF
Agomab Therapeutics said that it has closed an $89 million Series D financing round that will support development of several candidates, including its AGMB-447 inhaled ALK5 inhibitor for the treatment of idiopathic pulmonary fibrosis (IPF). New investors participating in the round included Sanofi and private equity investor Invus. In December 2023, Agomab … [Read more...] about Agomab raises $89 million for development of candidates including AGMB-447 inhaled ALK5 inhibitor for IPF
Orexo initiates study of OX640 epinephrine nasal powder in patients with allergic rhinitis
Orexo announces the initiation of the OX640-002 trial of OX640 epinephrine nasal powder in people with allergic rhinitis, with results expected in early 2025. The new trial is expected to enroll 30 people with allergic rhinitis and includes a test with a nasal allergen introduced prior to the epinephrine in order to compare the absorption of epinephrine with and … [Read more...] about Orexo initiates study of OX640 epinephrine nasal powder in patients with allergic rhinitis
Joshua Ziel joins Bryn Pharma as CEO
Intranasal epinephrine developer Bryn Pharma announced that former Aerami Therapeutics Chief Operating Officer Joshua Ziel has joined the company as CEO, succeeding Sandy Loreaux. Prior to joining Aerami in 2022, Ziel held management positions at Syneos Health and at advertising agency WPP. According to the company, Loreaux has resigned as CEO due to family matters … [Read more...] about Joshua Ziel joins Bryn Pharma as CEO
DDL 2024 to celebrate 35 years as a leading OINDP conference
The annual Drug Delivery to the Lungs (DDL) conference will mark its 35th anniversary during this year's meeting, which will take place December 11-13 at the Edinburgh International Conference Centre (EICC). Organizers have set a registration deadline of Sunday, November 10 to assist them in finalizing plans for a gala dinner celebrating the 35th anniversary. The … [Read more...] about DDL 2024 to celebrate 35 years as a leading OINDP conference
Transpire Bio names new VP of Manufacturing & Operations, Chief Commercial Officer, and Head of Quality Assurance
Inhaled drug developer Transpire Bio has announced the hires of Timothy Lutz as VP of Manufacturing and Operations; Stuart Loesch as Chief Commercial Officer; and Todd Sunstrom as Head of Quality Assurance. The company recently announced the initiation of a Phase 1 trial for a generic inhaler for asthma and COPD. Last October, Transpire officially opened its new … [Read more...] about Transpire Bio names new VP of Manufacturing & Operations, Chief Commercial Officer, and Head of Quality Assurance
Honeywell announces agreement to supply HFO 1234ze for DevPro albuterol MDI, spin off of the advanced materials business
Honeywell announced that it has signed a long-term supply agreement with DevPro Biopharma related to the use of Honeywell's Solstice Air HFO-1234ze in DevPro's DP007 albuterol metered dose inhaler. Earlier this year, DevPro and CDMO Bespak announced that they were collaborating on development of the LGWP propellant MDI. Recipharm, which later spun out Bespak, and … [Read more...] about Honeywell announces agreement to supply HFO 1234ze for DevPro albuterol MDI, spin off of the advanced materials business
A Q&A with Copley’s Clair Brooks on alternative BE approaches in new FDA guidance
A striking feature of recent batches of OINDP product specific guidances (PSGs) is the inclusion of strategies for the demonstration of bioequivalence (BE) that eliminate the need for a clinical endpoint trial. Copley Applications Specialist Clair Brooks discusses evolving test methods within this context, notably realistic aerodynamic particle size distribution … [Read more...] about A Q&A with Copley’s Clair Brooks on alternative BE approaches in new FDA guidance
Aptar acquires SipNose nasal delivery technology
Aptar Pharma announced that it has acquired nasal delivery technology from Israeli nasal drug developer SipNose Nasal Delivery Systems. In addition to developing devices, SipNose has a pipeline of candidates developed in-house and candidates in development with partners, such as Noveome's ST266 secretome. According to Aptar, the company has acquired all of … [Read more...] about Aptar acquires SipNose nasal delivery technology